Biogen vs Gilead Sciences
BIIB and GILD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIIB and GILD compare
Gilead Sciences is the larger company, worth 5.6 times as much as Biogen ($212B against $37.5B).
Gilead Sciences grew revenue faster over the last twelve months (5.5% versus 0.31% for Biogen).
Biogen keeps more of each dollar of sales as profit, with a net margin of 8.3% compared with −10.6% at Gilead Sciences.
Gilead Sciences pays a dividend yielding 1.9%; Biogen does not pay one.
Gilead Sciences scores higher on the StockData Score (11 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIIB | GILD |
|---|---|---|
| Size and price | ||
| Market cap | $37.5B | $212B |
| Share price | $253.62 | $170.68 |
| Change, 1 year | 71.5% | 44.0% |
| Change, 5 years | −9.0% | 157% |
| Beta (5Y) | 0.51 | 0.44 |
| Employees | 7,500 | 17K |
| StockData Score | ||
| Total score | 4 | 11 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 44.9× | – |
| P/S | 3.7× (better) | 6.9× |
| P/B | – | 17.9× |
| EV/EBITDA | 16.9× | – |
| P/FCF | 13.9× (better) | 16.4× |
| FCF yield | 7.2% (better) | 6.1% |
| Fair value | $157.62 | $83.31 |
| Margin of safety | −60.9% (better) | −105% |
| Growth | ||
| Revenue growth (TTM) | 0.31% | 5.5% (better) |
| Revenue growth, 5Y average | −6.0% | 3.6% (better) |
| Net income growth (TTM) | −45.5% (better) | −151% |
| EPS growth (TTM) | −46.0% (better) | −154% |
| EPS growth, 5Y average | −18.7% | 132% (better) |
| Profitability | ||
| Gross margin | 74.0% | 79.6% (better) |
| Operating margin | – | −8.2% |
| Net margin | 8.3% (better) | −10.6% |
| FCF margin | 26.9% | 42.5% (better) |
| Return on equity | – | −20.6% |
| Return on invested capital | – | −5.3% |
| Financial health | ||
| Debt / equity | – | 2.22 |
| Interest coverage | – | −2.5× |
| Current ratio | 1.87 (better) | 1.27 |
| Altman Z-score | 3.05 | 3.96 (better) |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.9% |
| Years of dividend growth | – | 11 |
| Dividend growth, 5Y average | – | 3.0% |
| Buyback yield | – | 0.54% |
| Shareholder yield | 0.00% | 2.4% (better) |
| Ownership | ||
| Held by institutions | 96.3% | 89.9% |
| Held by insiders | 0.21% | 0.10% |
| Insider net buying, 12 months | −$905K (better) | −$83.5M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 4.0% | 1.8% |
Go deeper
- BIIB stock overview
- BIIB income statement
- BIIB valuation and score
- GILD stock overview
- GILD income statement
- GILD valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.